PROPHY VAP: Ceftriaxone to prevent early ventilator associated pneumonia The Bottom Line The Challenge. The Evidence. The Solution. Ventilator Associated Pneumonia (VAP) remains a serious clinical issue in UK ICUs with NHS England data estimating 3,0006,000 deaths per year and treatment costs of 10,00020,000 Diagnosis, management and treatment of nosocomial pneumonia in ICU Serene Pharma's New Frontier How the VAP Market is Shaping the Future of Critical Care Ventilator associated pneumonia (VAP), a lung infection that develops in a person who is on a ventilator, can occur when germs enter through the tube and get into the patient's lungs. This is